Clinical Research Directory
Browse clinical research sites, groups, and studies.
N- Acetylcysteine in Airway Clearance in Broncheictasis
Sponsor: Assiut University
Summary
It has been deduced that reducing the production of mucus or improving the clearance of sputum in the airway is the key to enhance the therapeutic efficacy for bronchiectasis . Mucoactive drugs are commonly used to clear the airway in mucus hypersecretion diseases. Currently, investigators have found that N-acetylcysteine (NAC), an effective mucolytic agent, not only reduces the viscosity and elasticity of sputum, but it also has anti-inflammatory and antioxidant activity. Additionally, the Spanish guidelines on the treatment of bronchiectasis indicate that the use of N-acetylcysteine should be considered for patients with bronchiectasis and COPD. Therefore, as a classic mucolytic agent with antioxidant and anti-inflammatory properties, N-acetylcysteine can be effective in the treatment of bronchiectasis
Official title: Efficacy of Nebulized Versus Intravenous N- Acetylcysteine in Airway Clearance in Broncheictasis
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
70
Start Date
2025-12
Completion Date
2026-04
Last Updated
2025-12-19
Healthy Volunteers
No
Conditions
Interventions
N Acetyle cysteine given by IV injection
Arm: IV N Acetyle cysteine
Nebulized N Acetyle cysteine
Arm: Nebulized N Acetyle cysteine